Q1 2019 EPS Estimates for Neurocrine Biosciences, Inc. Raised by Oppenheimer (NBIX)

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Oppenheimer increased their Q1 2019 earnings per share estimates for Neurocrine Biosciences in a research report issued to clients and investors on Tuesday, March 12th. Oppenheimer analyst J. Olson now anticipates that the company will post earnings of ($1.03) per share for the quarter, up from their previous estimate of ($1.08). Oppenheimer has a “Outperform” rating and a $110.00 price objective on the stock. Oppenheimer also issued estimates for Neurocrine Biosciences’ Q4 2019 earnings at $0.55 EPS, FY2019 earnings at $1.04 EPS and FY2020 earnings at $3.92 EPS.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Tuesday, February 5th. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.05. The company had revenue of $131.49 million during the quarter, compared to analysts’ expectations of $132.32 million. Neurocrine Biosciences had a return on equity of 5.06% and a net margin of 4.68%. Neurocrine Biosciences’s quarterly revenue was up 39.1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.07 EPS.

Several other equities research analysts have also recently weighed in on NBIX. BidaskClub cut Neurocrine Biosciences from a “hold” rating to a “sell” rating in a report on Friday, November 16th. Canaccord Genuity started coverage on Neurocrine Biosciences in a report on Wednesday, November 21st. They issued a “buy” rating and a $111.00 price objective for the company. Cantor Fitzgerald set a $150.00 price objective on Neurocrine Biosciences and gave the stock a “buy” rating in a report on Wednesday, December 5th. Needham & Company LLC set a $104.00 price objective on Neurocrine Biosciences and gave the stock a “buy” rating in a report on Wednesday, December 12th. Finally, Stifel Nicolaus dropped their price objective on Neurocrine Biosciences from $115.00 to $17.07 and set a “buy” rating for the company in a report on Wednesday, December 12th. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $102.56.

Shares of NBIX stock opened at $84.39 on Friday. Neurocrine Biosciences has a 1-year low of $64.72 and a 1-year high of $126.98. The company has a debt-to-equity ratio of 0.81, a current ratio of 8.36 and a quick ratio of 8.24. The stock has a market cap of $7.60 billion, a P/E ratio of 383.59, a P/E/G ratio of 29.63 and a beta of 1.86.

Several institutional investors and hedge funds have recently added to or reduced their stakes in NBIX. Norges Bank purchased a new position in shares of Neurocrine Biosciences in the 4th quarter valued at approximately $61,171,000. Orbimed Advisors LLC increased its position in Neurocrine Biosciences by 258.6% during the 4th quarter. Orbimed Advisors LLC now owns 494,200 shares of the company’s stock valued at $35,291,000 after buying an additional 356,400 shares in the last quarter. Thrivent Financial for Lutherans increased its position in Neurocrine Biosciences by 94.5% during the 4th quarter. Thrivent Financial for Lutherans now owns 691,851 shares of the company’s stock valued at $49,405,000 after buying an additional 336,101 shares in the last quarter. First Trust Advisors LP increased its position in Neurocrine Biosciences by 27.3% during the 4th quarter. First Trust Advisors LP now owns 1,299,455 shares of the company’s stock valued at $92,794,000 after buying an additional 278,598 shares in the last quarter. Finally, Capital International Investors bought a new position in Neurocrine Biosciences during the 3rd quarter valued at approximately $31,721,000.

In other news, insider Kyle Gano sold 3,809 shares of the firm’s stock in a transaction that occurred on Tuesday, February 5th. The stock was sold at an average price of $88.12, for a total value of $335,649.08. Following the completion of the transaction, the insider now owns 17,595 shares in the company, valued at approximately $1,550,471.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Kevin Charles Gorman sold 7,614 shares of the firm’s stock in a transaction that occurred on Tuesday, February 5th. The shares were sold at an average price of $88.16, for a total value of $671,250.24. Following the completion of the transaction, the chief executive officer now owns 408,082 shares of the company’s stock, valued at approximately $35,976,509.12. The disclosure for this sale can be found here. In the last 90 days, insiders sold 13,280 shares of company stock valued at $1,163,054. 4.30% of the stock is currently owned by company insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Recommended Story: Derivative

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.